The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTNT.L Regulatory News (TNT)

  • There is currently no data for TNT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Science Officer

27 Jun 2022 07:00

RNS Number : 2594Q
Tintra PLC
27 June 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

 

27 June 2022

TINTRA PLC

 ("Tintra", the "Group" or the "Company")

 

Appointment of Chief Science Officer

 

 

The board of directors (the "Board") of Tintra, the rapidly innovating Banking & Technology business, is pleased to announce the appointment yesterday of Dr Joe Lyske as Chief Science Officer ("CSO") and a Director of the Company as the Group continues to execute its plan to build global banking infrastructure driven by Artificial Intelligence and Natural Language Processing tools.

 

Dr Lyske is a co-founder of Time Machine Capital 2 Limited, the Company's joint venture partner in Tintra 3.0. It is through this relationship that he first joined the Group's activities as part of the Tintra 3.0 Ltd team, the artificial intelligence ("AI") joint venture announced on 24 November 2021, where he made a considerable contribution to the patent application announced on 16 June 2022.

 

Dr Lyske was until recently CTO of Triller, a US based video-sharing social networking app, as well as CEO and Co-founder of Mashtraxx. 

 

He has invented and patented several creative AI core technologies one of which resulting in the world's first AI engine that atomises, re-constructs and edits any music to video, instantly.

 

Dr Lyske holds a PhD in Artificial Intelligence from Queen Mary, University of London, and an Advanced Masters in Composition for Screen from the Royal College of Music. In addition to his achievements in the technology space, he has pursued successful careers in both academia and music.

 

Dr Lyske said, "I am very pleased to be taking this step with Tintra as we continue to focus on building technology that enacts real change. 

Tintra's mission of building a banking platform that sees the world as it is rather than through a distorted lens is the right mission at the right time in my view. I have seen first-hand these preconceptions written in the very code of historical banking infrastructure. I look forward to being involved with a project that does not hide behind phrases like 'legacy infrastructure' as an excuse for domestic protectionism. 

Just as institutionalised prejudices in an organisation can only be changed if the culture of the organisation is changed technologically architectured preconceptions can only change if we embrace new technologies, and stop hiding behind the word "legacy", as if it is an adequate excuse for a technological bigotry that causes real human discrimination and harm.

Using weighted averages to blanket-analyse whole countries' populations and businesses is a lazy way to assess risk, and we as a society can and should do better.

Tintra's goal of doing that is one that I am passionate about. I look forward to building the technology to allow this to happen."

Richard Shearer, Tintra's CEO, said, "Using technology to create a better future is something that has become a familiar retort across the world and is a goal that should be encouraged. However, some sectors have had more success than others in achieving this goal.

 

In financial services, actually effecting positive change is perhaps harder than in any other verticals. So it is not to our competitors' detriment that true emerging market fiscal inclusion is still something that is little more than a notion. It's a big challenge that requires new thinking.

 

As a company we are closer than most to what the challenges are in these markets and what needs to be achieved to create this level fiscal playing field. Having this pursuit as our North Star is one thing but it requires a team of people across a range of disciplines to make it work.

 

Throughout this year, we have therefore built a team of great minds across a range of disciplines, from technologists, to futurists, geopoliticians, ethnographers, regulatory specialists, and beyond. All of whom share our vision to create true fiscal inclusion across emerging markets, unencumbered by legacy thinking.

 

We will only do good for people once we have built the infrastructure that will make this change.

 

To this end, welcoming Dr Lyske to our board is a major step toward delivering on our vision. Joe shares my passion about building a multi-billion-dollar business over the next few years - but that sits secondary to the goal of creating a business that creates true fiscal inclusion across the world. 

 

Joe has invented dozens of AI processes and technologies across a range of disciplines and his leadership abilities have become evident through our work together over the past six months or so. Perhaps equally important, Joe has recently served as CTO of a company that scaled from a few dozen to many hundreds in a very short period of time, something that we are looking to replicate over the coming 12-18 months.

I am delighted to welcome Joe to the board today, and I look forward to working with him as we create Artificial Intelligence to enact Real Change™."

 

 

 

For further information, contact:

 

Tintra PLC

(Communications Head)

Hannah Haffield

h.haffield@tintra.com

Website www.tintra.com

020 3795 0421

 

Allenby Capital Limited

(Nomad, Financial Adviser & Broker)

John Depasquale / Nick Harriss / Vivek Bhardwaj

 

020 3328 5656

 

Regulatory disclosures 

 

In accordance with Schedule 2(g) of the AIM Rules, Dr Joseph Michael William Lyske, known as ''Joe'', (previous surname, "Molloy" as a child) (aged 47) holds, or has held in the past 5 years, the following directorships and partnerships: 

 

Current 

Past five years 

Dacci Ltd

 

Dormantai Ltd

 

Mashtraxx Limited

 

Mashtraxx (Triller Holding) Limited *

 

Time Machine Capital Limited *

 

Time Machine Capital Squared LLP

(LLP designated member)

 

(* Currently subject to solvent

Members' Voluntary Liquidation)

 Eevsy Ltd

 

Time Machine AI LLP

(LLP designated member) 

 

Dr Lyske holds 18,500 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") (equivalent to 0.12% of the issued ordinary share capital). In addition, he is a founder and person of significant control, but not a director, of Time Machine Capital 2 Limited, which holds 636,475 Ordinary Shares (equivalent to 4.29% of the issued ordinary share capital) and 636,475 warrants (full details as announced 24 November 2021).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGUGDLLUDDGDR
Date   Source Headline
8th Jan 20247:00 amRNSCancellation - Tintra plc
4th Jan 20241:21 pmRNSResult of General Meeting 4 January 2024
27th Dec 20237:00 amRNSUpdate on Proxy Votes Re: Special Resolutions
14th Dec 20236:01 pmRNSProxy votes relating to Special Resolutions
7th Dec 20232:20 pmRNSGeneral Meeting & Matched Bargain Facility
6th Dec 202311:02 amRNSResignation of Nominated Adviser and Broker
6th Dec 20239:04 amRNSCirc re. General Meeting
28th Nov 20236:00 pmRNSIntention to Seek Cancellation from Trading on AIM
6th Nov 20237:24 amRNSRule 2.8 and Proposed Tender Offer
6th Nov 20237:00 amRNSTender Offer replaces Possible Offer & AIM delist
2nd Nov 20234:14 pmRNSResult of Adjourned AGM and GM
31st Oct 20236:16 pmRNSHalf-year Report to 31 July 2023
20th Oct 202311:54 amRNSPCA/PDMR Dealing & Holding in Company
19th Oct 202310:44 amRNSForm 8.3 - TINTRA PLC Amendment
17th Oct 20236:00 pmRNSNotice of Reconvened AGM & Notice of GM
11th Oct 20233:37 pmRNSForm 8.3 - TINTRA PLC
6th Oct 20234:06 pmRNSForm 8 (DD) - Offeree Concert Party - Tintra plc
6th Oct 20239:35 amRNSForm 8 (DD) - Offeree Concert Party - Tintra plc
5th Oct 20231:35 pmRNSForm 8.3 - TINTRA PLC
5th Oct 202310:32 amRNSForm 8 (DD) - Offeree Concert Party - Tintra plc
5th Oct 20237:00 amRNSExtension of PUSU deadline pursuant to Rule 2.6(c)
3rd Oct 202310:15 amRNSResumption of Trading on AIM
3rd Oct 202310:15 amRNSRestoration - Tintra plc
2nd Oct 20233:30 pmRNSAnnual Financial Report for the year to 31 Jan 23
2nd Oct 20231:00 pmRNSForm 8.3 - Tintra plc - Empire Global
29th Sep 202311:33 amRNSForm 8.3 - Tintra PLC
29th Sep 202311:03 amRNSForm 8 (DD) - Offeree Concert Party - Tintra PLC
29th Sep 202310:46 amRNSForm 8.3 - Offeree - Updated
29th Sep 202310:45 amRNSDirector/PDMR Shareholding
27th Sep 202311:30 amRNSForm 8.3 - Tintra plc - Crescent Moon Ventures
26th Sep 20237:00 amRNSForm 8 (OPD) Offeror - Tintra PLC
25th Sep 20232:30 pmRNSTechnology Partnership Agreement
25th Sep 20232:26 pmRNSForm 8.3 - Tintra plc - A Stuart-Bamford
25th Sep 20232:15 pmRNSForm 8.3 - Tintra plc - P Jackson
21st Sep 20236:23 pmRNSForm 8 (OPD) - Tintra Plc
14th Sep 20231:35 pmRNSForm 8.3 - Tintra PLC
7th Sep 20231:30 pmRNSStatement re Possible Offer
1st Sep 202311:30 amRNSFurther re Audited Accounts to 31 Jan 2023
31st Aug 20235:00 pmRNSRevised Financing Arrangement
10th Aug 20237:00 amRNSPlacement Facility Update
1st Aug 20237:30 amRNSSuspension - Tintra plc
31st Jul 20235:30 pmRNSConversion of Securities
31st Jul 202312:00 pmRNSResult of AGM
31st Jul 20239:00 amRNS12 Month Unaudited Results to 31 January 2023
19th Jul 20232:00 pmRNSExpected delay in publication of Annual Report
11th Jul 20237:00 amRNSSubscription Update
7th Jul 20237:00 amRNSNotice of AGM and Directorate & Management Change
5th Jul 20237:00 amRNSRepayment & Termination of Placement Facility
30th Jun 20239:00 amRNSDirectorate & Management Change
9th Jun 20233:43 pmRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.